Study identification

EU PAS number

EUPAS1000000603

Study ID

1000000603

Official title and acronym

Long-term outcomes in patients continuously treated with ADVAGRAF following a liver transplant in routine clinical practice in Spain: a multicenter secondary data (chart review) cohort study

DARWIN EU® study

No

Study countries

Spain

Study description

ADVAGRAF is a medicine given to people just after they receive a liver transplant to stop the immune system from rejecting the new liver.
This study will use information from clinics in Spain to learn more about the outcomes of people treated with ADVAGRAF after their liver transplant in Spain. This type of study is called a real-world study.
Information will be collected from medical records from the start of ADVAGRAF treatment until the transplant failed, treatment stopped, or until 31 December 2024.

Study status

Ongoing
Research institutions and networks

Institutions

Astellas Pharma Europe Ltd.

Networks

N/A

Contact details

Alexander Harkavyi

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual:

Study start date

Actual:

Data analysis start date

Planned:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable